Author:
Azevedo Valderilio,Hassett Brian,Fonseca João Eurico,Atsumi Tatsuya,Coindreau Javier,Jacobs Ira,Mahgoub Ehab,O’Brien Julie,Singh Ena,Vicik Steven,Fitzpatrick Brian
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference37 articles.
1. Morrow T, Felcone LH (2004) Defining the difference: what makes biologics unique. Biotechnol Healthc 1:24–29
2. Kuhlmann M, Covic A (2006) The protein science of biosimilars. Nephrol Dial Transplant 21(Suppl 5):v4–8. doi: 10.1093/ndt/gfl474
3. US Food and Drug Admiistration, Troy DE (2013) Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). US Department of Heralth & Human Services. http://www.fda.gov/newsevents/testimony/ucm115033.htm . Accessed 5 July 2016
4. US Food and Drug Administration (2011) Submission of summary bioequivalence data for ANDAs. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM134846.pdf . Accessed 5 July 2016
5. Morais JA, Lobato Mdo R (2010) The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol 106:221–225. doi: 10.1111/j.1742-7843.2009.00518.x
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献